interferon induced transmembrane protein 2Genealiases: 1-8D · DSPA2c
Q-omics provides the consensus-scored IFITM2 profile across patient tissues and cancer cell-line models. IFITM2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IFITM2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, IFITM2 RNA expression shows 23,019 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KICH, and LSCC as cancer lineages where IFITM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFITM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFITM2 survival associations across molecular data types. IFITM2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFITM2 RNA expression–survival associations across cancer types. High IFITM2 expression shows unfavorable associations in KIRP, LGG and LUSC, but favorable associations in MESO, UCEC and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IFITM2 RNA expression.
This table summarizes IFITM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IFITM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFITM2 shows lower tumor expression in KICH, LUSC, UCEC and LUAD and higher tumor expression in COAD and KIRC. The KICH box plot shows higher IFITM2 RNA expression in normal versus tumor tissue (log2 FC = −2.977, t-test p < 0.001).
This table shows molecular features associated with IFITM2 in patient tissues and cancer cell lines. In patient samples, IFITM2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFITM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
